1. Segal E: Candida, still number one–what do we know and where are we going from there? Mycoses 48(Suppl 1):3-11, 2005
2. Farah CS, Ashman RB, Challacombe SJ: Oral candidosis. Clin Dermatol 18(5):553-562, 2000
3. Fidel PL Jr, Sobel JD: Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 9(3):335-348, 1996
4. Grigoriou O et al: Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 126(1):121-125, 2006
5. Patton LL, van der Horst C: Oral infections and other manifestations of HIV disease. Infect Dis Clin North Am 13(4):879-900, 1999
6. de Repentigny L, Lewandowski D, Jolicoeur P: Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 17(4):729-759, table of contents, 2004
7. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 20(1):133-163, 2007
8. Vazquez JA, Candidiasis SJ: Clinical Mycology, edited by PP Dismukes WE, JD Sobel. Oxford Univers, 2003, pp. 143-187.
9. Yang YL: Virulence factors of Candida species. J Microbiol Immunol Infect 36(4):223-228, 2003
10. De Bernardis F et al: Biotyping and virulence properties of skin isolates of Candida parapsilosis. J Clin Microbiol 37(11):3481-3486, 1999
11. Kullberg BJ, Oude Lashof AM: Epidemiology of opportunistic invasive mycoses. Eur J Med Res 7(5):183-191, 2002
12. Sullivan DJ et al: Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 4(4-5):369-376, 2004
13. Pappas PG et al: A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37(5):634-643, 2003
14. Pappas PG: Invasive candidiasis. Infect Dis Clin North Am 20(3):485-506, 2006
15. Appleton SS: Candidiasis: Pathogenesis, clinical characteristics, and treatment. J Calif Dent Assoc 28(12):942-948, 2000
16. Belazi M et al: Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: Prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol 19(6):347-351, 2004
17. McCullough MJ, Savage NW: Oral candidosis and the therapeutic use of antifungal agents in dentistry. Aust Dent J 50(4 Suppl 2):S36-S39, 2005
18. Webb BC, Thomas CJ, Whittle T: A 2-year study of Candida-associated denture stomatitis treatment in aged care subjects. Gerodontology 22(3):168-176, 2005
19. Wilson J: The aetiology, diagnosis and management of denture stomatitis. Br Dent J 185(8):380-384, 1998
20. Ferrer J: Vaginal candidosis: Epidemiological and etiological factors. Int J Gynaecol Obstet 71(Suppl 1):S21-S27, 2000
21. Haefner HK: Current evaluation and management of vulvovaginitis. Clin Obstet Gynecol 42(2):184-195, 1999
22. MacDonald TM et al: The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q J Med 86(7):419-424, 1993
23. Spinillo A et al: Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstet Gynecol 81(5 (Pt 1)):721-727, 1993
24. Owen MK, Clenney TL: Management of vaginitis. Am Fam Physician 70(11):2125-2132, 2004
25. Sobel JD: Vulvovaginal candidosis. Lancet 369(9577):1961-1971, 2007
26. Pariser DM: Cutaneous candidiasis. A practical guide for primary care physicians. Postgrad Med 87(6):101-103, 106-108, 1990
27. Kazaks EL, Lane AT: Diaper dermatitis. Pediatr Clin North Am 47(4):909-919, 2000
28. Giandoni MB, Grabski WJ: Cutaneous candidiasis as a cause of delayed surgical wound healing. J Am Acad Dermatol 30(6):981-984, 1994
29. Hay RJ: Yeast infections. Dermatol Clin 14(1):113-124, 1996
30. Elewski BE: Onychomycosis: Pathogenesis, diagnosis, and management. Clin Microbiol Rev 11(3):415-429, 1998
31. Kirkpatrick CH: Chronic mucocutaneous candidiasis. J Am Acad Dermatol 31(3 Pt 2):S14-S17, 1994
32. Kirkpatrick CH: Chronic mucocutaneous candidiasis. Eur J Clin Microbiol Infect Dis 8(5):448-456, 1989
33. Herrod HG: Chronic mucocutaneous candidiasis in childhood and complications of non-Candida infection: A report of the Pediatric Immunodeficiency Collaborative Study Group. J Pediatr 116(3):377-382, 1990
34. Durandy A et al: Mannan-specific and mannan-induced T-cell suppressive activity in patients with chronic mucocutaneous candidiasis. J Clin Immunol 7(5):400-409, 1987
35. Richardson MD: Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56(Suppl 1):i5-i11, 2005
36. Wright WL, Wenzel RP: Nosocomial Candida. Epidemiology, transmission, and prevention. Infect Dis Clin North Am 11(2):411-425, 1997
37. Kressel B, Szewczyk C, Tuazon CU: Early clinical recognition of disseminated candidiasis by muscle and skin biopsy. Arch Intern Med 138(3):429-433, 1978
38. Alexander BD: Diagnosis of fungal infection: New technologies for the mycology laboratory. Transpl Infect Dis 4(Suppl 3):32-37, 2002
39. Odabasi Z et al: Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39(2):199-205, 2004
40. Pappas PG et al: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48(5):503-535, 2009
41. Chandrasekar PH, Sobel JD:
Micafungin: A new echinocandin.
Clin Infect Dis 42(8):1171-1178, 2006
42. Vazquez JA, Sobel JD:
Anidulafungin: A novel echinocandin.
Clin Infect Dis 43(2):215-222, 2006
43. Sobel JD: Controversial aspects in the management of vulvovaginal candidiasis. J Am Acad Dermatol 31(3 Pt 2):S10-S13, 1994
44. Welsh O, Vera-Cabrera L, Welsh E: Onychomycosis. Clin Dermatol 28(2):151-159, 2010
45. Keating G, Figgitt D:
Caspofungin: A review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Drugs 63(20):2235-2263, 2003
46. Hirai A et al: Malassezia nana sp. nov., a novel lipid-dependent yeast species isolated from animals. Int J Syst Evol Microbiol 54(Pt 2):623-627, 2004
47. Sugita T et al: A new yeast, Malassezia yamatoensis, isolated from a patient with seborrheic dermatitis, and its distribution in patients and healthy subjects. Microbiol Immunol 48(8):579-583, 2004
48. Sugita T et al: Description of a new yeast species, Malassezia japonica, and its detection in patients with atopic dermatitis and healthy subjects. J Clin Microbiol 41(10):4695-4699, 2003
49. Gupta AK et al: Skin diseases associated with Malassezia species. J Am Acad Dermatol 51(5):785-798, 2004
50. Batra R et al: Malassezia Baillon, emerging clinical yeasts. FEMS Yeast Res 5(12):1101-1113, 2005
51. Gueho E, Midgley G, Guillot J: The genus Malassezia with description of four new species. Antonie Van Leeuwenhoek 69(4):337-355, 1996
52. Cafarchia C, Otranto D: Association between phospholipase production by Malassezia pachydermatis and skin lesions. J Clin Microbiol 42(10):4868-4869, 2004
53. Chang HJ et al: An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers' pet dogs. N Engl J Med 338(11):706-711, 1998
54. Morris DO: Malassezia pachydermatis carriage in dog owners. Emerg Infect Dis 11(1):83-88, 2005
55. Crespo Erchiga V et al: Malassezia globosa as the causative agent of pityriasis versicolor. Br J Dermatol 143(4):799-803, 2000
56. Niamba P et al: Is common neonatal cephalic pustulosis (neonatal acne) triggered by Malassezia sympodialis? Arch Dermatol 134(8):995-998, 1998
57. Bernier V et al: Skin colonization by Malassezia species in neonates: A prospective study and relationship with neonatal cephalic pustulosis. Arch Dermatol 138(2):215-218, 2002
58. Levin NA: Beyond spaghetti and meatballs: Skin diseases associated with the Malassezia yeasts. Dermatol Nurs 21(1):7-13, 51; quiz 14, 2009
59. Sunenshine PJ, Schwartz RA, Janniger CK: Tinea versicolor. Int J Dermatol 37(9):648-655, 1998
60. Nakabayashi A, Sei Y, Guillot J: Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol 38(5):337-341, 2000
61. Gupta AK, Bluhm R, Summerbell R: Pityriasis versicolor. J Eur Acad Dermatol Venereol 16(1):19-33, 2002
62. Schmidt A: Malassezia furfur: A fungus belonging to the physiological skin flora and its relevance in skin disorders. Cutis 59(1):21-24, 1997
63. Mayser P et al: Pityriacitrin – an ultraviolet-absorbing indole alkaloid from the yeast Malassezia furfur. Arch Dermatol Res 294(3):131-134, 2002
64. Mendez-Tovar LJ: Pathogenesis of dermatophytosis and tinea versicolor. Clin Dermatol 28(2):185-189, 2010
65. Crespo-Erchiga V, Florencio VD: Malassezia yeasts and pityriasis versicolor. Curr Opin Infect Dis 19(2):139-147, 2006
66. Sunenshine PJ, Schwartz RA, Janniger CK: Tinea versicolor: An update. Cutis 61(2):65-68, 71-72, 1998
67. Burkhart CG, Dvorak N, Stockard H: An unusual case of tinea versicolor in an immunosuppressed patient. Cutis 27(1):56-58, 1981
68. Hull CA, Johnson SM: A double-blind comparative study of sodium
sulfacetamide lotion 10% versus
selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor.
Cutis 73(6):425-429, 2004
69. Gupta AK, Skinner AR:
Ciclopirox for the treatment of superficial fungal infections: A review.
Int J Dermatol 42(Suppl 1):3-9, 2003
70. Carrillo-Munoz AJ et al:
Sertaconazole: Updated review of a topical antifungal agent.
Expert Rev Anti Infect Ther 3(3):333-342, 2005
71. Lange DS et al:
Ketoconazole 2% shampoo in the treatment of tinea versicolor: A multicenter, randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol 39(6):944-950, 1998
72. Savin R et al: Tinea versicolor treated with
terbinafine 1% solution.
Int J Dermatol 38(11):863-865, 1999
73. Drake LA et al: Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol 34(2 Pt 1):287-289, 1996
74. Karakas M, Durdu M, Memisoglu HR: Oral
fluconazole in the treatment of tinea versicolor.
J Dermatol 32(1):19-21, 2005
75. Fernandez-Nava HD, Laya-Cuadra B, Tianco EA: Comparison of single dose 400 mg versus 10-day 200 mg daily dose
ketoconazole in the treatment of tinea versicolor.
Int J Dermatol 36(1):64-66, 1997
76. Hickman JG: A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral
itraconazole in patients with tinea versicolor.
J Am Acad Dermatol 34(5 Pt 1):785-787, 1996
77. Kose O et al: Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of
itraconazole in the treatment of tinea versicolor.
J Dermatolog Treat 13(2):77-79, 2002
78. Partap R et al: Single-dose
fluconazole versus
itraconazole in pityriasis versicolor.
Dermatology 208(1):55-59, 2004
79. Mellen LA et al: Treatment of pityriasis versicolor in the United States. J Dermatolog Treat 15(3):189-192, 2004
80. Faergemann J et al: Efficacy of
itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor.
Arch Dermatol 138(1):69-73, 2002
81. Bulmer GS, Pu XM, Yi LX: Malassezia folliculitis in China. Mycopathologia 165(6):411-412, 2008
82. Akaza N et al: Malassezia folliculitis is caused by cutaneous resident Malassezia species. Med Mycol 47(6):618-624, 2009
83. Ayers K, Sweeney SM, Wiss K: Pityrosporum folliculitis: Diagnosis and management in 6 female adolescents with acne vulgaris. Arch Pediatr Adolesc Med 159(1):64-67, 2005
84. Helm KF, Lookingbill DP: Pityrosporum folliculitis and severe pruritus in two patients with Hodgkin's disease. Arch Dermatol 129(3):380-381, 1993
85. Cholongitas E, Pipili C, Ioannidou D: Malassezia folliculitis presented as acneiform eruption after
cetuximab administration.
J Drugs Dermatol 8(3):274-275, 2009
86. Parlak AH, Boran C, Topcuoglu MA: Pityrosporum folliculitis during pregnancy: A possible cause of pruritic folliculitis of pregnancy. J Am Acad Dermatol 52(3 Pt 1):528-529, 2005
87. Faergemann J: Pityrosporum species as a cause of allergy and infection. Allergy 54(5):413-419, 1999